Friday, 10 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > Europe’s last maker of key antibiotics ingredients shuts biggest domestic factory
Economy

Europe’s last maker of key antibiotics ingredients shuts biggest domestic factory

Last updated: May 6, 2025 8:10 am
Share
Europe’s last maker of key antibiotics ingredients shuts biggest domestic factory
SHARE

Europe’s last manufacturer of ingredients for some vital antibiotics is closing its biggest domestic factory and shifting some production to China, dealing a blow to Brussels’ efforts to reduce drug dependence on Asia.

Lossmaking Xellia Pharmaceuticals said it could only survive against Chinese competition by moving some of its production to its plant there.

Half of Xellia’s active pharmaceutical ingredients (APIs) feature on the recent EU list of critical medicines and the World Health Organization’s list of essential medicines.

The Danish company told staff on Tuesday that it would shut its Copenhagen plant, resulting in a loss of 500 jobs. For now, it will retain a more cost-efficient European operation in Budapest.

Its chief executive Michael Kocher said that unless government-funded health systems were prepared to pay more for generic medicines, more companies based in the EU would move factories.

“We are discussing so much about reshoring. I think it’s just as important to make sure that what we have in Europe stays in Europe,” he told the Financial Times in an interview.

The medicine ingredients Xellia makes includes vancomycin hydrochloride, which is needed to produce antibiotics that can treat severe infections such as sepsis, which are resistant to other drugs.

About 80 per cent of APIs used in the EU already come from China. With strained health systems unwilling to increase medicine prices, Kocher suggested that subsidies were the only way to ensure the EU retained some control over such important ingredients.

“Otherwise, not just 80 per cent of the APIs will come from China. It will be close to 100 per cent very soon,” he said.

See also  Tesla sends driverless Model Y from factory to customer to promote its robotaxi tech

Western demand for vancomycin hydrochloride could still be met from Budapest if market conditions improved, Kocher stressed.

The European Commission in March unveiled proposals that could be included in a Critical Medicines Act to try to address dependencies exposed by the Covid-19 pandemic, when countries ran short of medicines, protective clothing, and equipment such as ventilators.

These proposals aim to increase EU production of more than 200 medicines, from antibiotics such as penicillin and erythromycin, to painkillers such as lidocaine and morphine.

The measures discussed include allowing countries to join up to make bulk purchases, and favoring EU-made products in procurement processes. But Kocher said the policies were too timid and taking too long to implement.

“Costs are increasing, you try to transfer these costs to your customer and then your customers decide the costs are too high and increase the share coming from China,” he said. “We are seeking a commitment to support ongoing operations.”

Research-intensive pharmaceutical companies have also warned that low prices paid by European health systems are driving new drug discovery efforts to the US and China.

The chief executives of Novartis and Sanofi wrote to the commission last month to call for higher prices. They also pointed out that US tariffs were prompting companies to invest in North America. However, Xellia said it had no plans to do the same.

Xellia, which is owned by Novo Holdings, the controlling shareholder of Danish pharmaceutical powerhouse Novo Nordisk, sells to more than 500 businesses in 80 countries. It will take a decade to slowly transfer production from its Copenhagen factory elsewhere.

See also  The Kroger Co. (KR) Shuts Down Home Delivery Service Offering

Kocher said the EU should put more value on its “life-saving” products that treat meningitis and other lethal conditions. “Without our product portfolio, we would be faced with a huge challenge. Covid would be a small issue in comparison,” he said.

TAGGED:antibioticsBiggestDomesticEuropesFactoryIngredientsKeymakerShuts
Share This Article
Twitter Email Copy Link Print
Previous Article Wetlands and Streams Face a New Threat from the Trump Administration Wetlands and Streams Face a New Threat from the Trump Administration
Next Article Inflation and the Demand for Money: The Confederacy in the Civil War Inflation and the Demand for Money: The Confederacy in the Civil War
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Why Shares in Novo Nordisk Bumped Higher Today

Novo Nordisk is significantly enhancing its footprint in the U.S. manufacturing industry with plans for…

October 3, 2025

Xiaomi’s new flagship killer tablet needs to go global. Here’s why

Xiaomi has recently unveiled its latest flagship smartphones in China, but let’s not overlook its…

September 26, 2025

National success for Otago secondary school weightlifters

The National Secondary School Weightlifting Championships brought together young talent from all corners of New…

September 12, 2024

‘Rust’ Shooting Story Revealed in New Trailer for Hulu Documentary

The tragic accident on the set of the film "Rust" that resulted in the death…

February 28, 2025

Physicist May Have Solved The Grandfather of All Time-Travel Paradoxes : ScienceAlert

Revisiting the Grandfather Paradox: Is Time Travel Really Impossible? Time travel has always been a…

January 18, 2025

You Might Also Like

This NYSE-Listed Food Company Aims to Stack .2 Billion in Bitcoin
Economy

This NYSE-Listed Food Company Aims to Stack $1.2 Billion in Bitcoin

October 10, 2025
Tennessee bomb factory explosion leaves as many as 19 feared missing or dead
World News

Tennessee bomb factory explosion leaves as many as 19 feared missing or dead

October 10, 2025
Adidas to Enter Safety Footwear in 2026 With New ‘Pro Work’ Line
Economy

Adidas to Enter Safety Footwear in 2026 With New ‘Pro Work’ Line

October 10, 2025
Elon Musk and former Twitter execs agree to settle 8 million lawsuit
Economy

Elon Musk and former Twitter execs agree to settle $128 million lawsuit

October 10, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?